Immunotherapy with NK cells: recent developments in gene modification open up new avenues

被引：32

作者：

Reindl, Lisa Marie ^{[1
,2
]}

Albinger, Nawid ^{[1
,2
]}

Bexte, Tobias ^{[1
,2
]}

Mueller, Stephan ^{[1
,2
]}

Hartmann, Jessica ^{[3
]}

Ullrich, Evelyn ^{[1
,2
,4
]}

机构：

[1] Goethe Univ Frankfurt, Childrens Hosp, Frankfurt, Germany

[2] Goethe Univ Frankfurt, Expt Immunol, Frankfurt, Germany

[3] Paul Ehrlich Inst, Div Med Biotechnol, Langen, Germany

[4] Goethe Univ, Frankfurt Canc Inst, Frankfurt, Germany

来源：

ONCOIMMUNOLOGY | 2020年 / 9卷 / 01期

关键词：

CAR; NK cells; NK-92; cells; cell therapy; NATURAL-KILLER-CELL; CHIMERIC ANTIGEN RECEPTOR; T-CELLS; MESSENGER-RNA; NK-92; CELLS; HEMATOPOIETIC-CELLS; CORD BLOOD; IN-VITRO; ADOPTIVE TRANSFER; VIVO EXPANSION;

D O I：

10.1080/2162402X.2020.1777651

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chimeric antigen receptor (CAR)-T cell therapies have achieved remarkable success. However, application-related toxicities, such as cytokine release syndrome or neurotoxicity, moved natural killer (NK) cells into focus as novel players in immunotherapy. CAR-NK cells provide an advantageous dual killing-capacity by CAR-dependent and -independent mechanisms and induce few side effects. While the majority of trials still use CAR-T cells, CAR-NK cell trials are on the rise with 19 ongoing studies worldwide. This review illuminates the current state of research and clinical application of CAR-NK cells, as well as future developmental potential.

引用

页数：12

共 120 条

[1] The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules:: implications for tumor immune escape [J].

Algarra, I ;

García-Lora, A ;

Cabrera, T ;

Ruiz-Cabello, F ;

Garrido, F .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (10) :904-910

[2]

[Anonymous], 2017, ASH ANN M

[3]

Antony GK, 2010, CURR MED CHEM, V17, P3297

[4]

Arnon TI, 2001, EUR J IMMUNOL, V31, P2680, DOI 10.1002/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO

[5]

2-A

[6] Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors [J].

Balakrishnan, Ashwini ;

Rajan, Anusha ;

Salter, Alexander I. ;

Kosasih, Paula L. ;

Wu, Qian ;

Voutsinas, Jenna ;

Jensen, Michael C. ;

Pluckthun, Andreas ;

Riddell, Stanley R. .

CLINICAL CANCER RESEARCH, 2019, 25 (24) :7506-7516

[7] A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy [J].

Bari, Rafijul ;

Granzin, Markus ;

Tsang, Kam Sze ;

Roy, Andre ;

Krueger, Winfried ;

Orentas, Rimas ;

Pfeifer, Rita ;

Moeker, Nina ;

Verhoeyen, Els ;

Dropulic, Boro ;

Leung, Wing .

FRONTIERS IN IMMUNOLOGY, 2019, 10

[8]

BEANO A, 2008, J TRANSL MED, V6, DOI DOI 10.1186/1479-5876-6- 25

[9] Deep immune profiling by mass cytometry links human T and NK cell differentiation and cytotoxic molecule expression patterns [J].

Bengsch, Bertram ;

Ohtani, Takuya ;

Herati, Ramin Sedaghat ;

Bovenschen, Niels ;

Chang, Kyong-Mi ;

Wherry, E. John .

JOURNAL OF IMMUNOLOGICAL METHODS, 2018, 453 :3-10

[10] The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody [J].

Benson, Don M., Jr. ;

Bakan, Courtney E. ;

Mishra, Anjali ;

Hofmeister, Craig C. ;

Efebera, Yvonne ;

Becknell, Brian ;

Baiocchi, Robert A. ;

Zhang, Jianying ;

Yu, Jianhua ;

Smith, Megan K. ;

Greenfield, Carli N. ;

Porcu, Pierluigi ;

Devine, Steven M. ;

Rotem-Yehudar, Rinat ;

Lozanski, Gerard ;

Byrd, John C. ;

Caligiuri, Michael A. .

BLOOD, 2010, 116 (13) :2286-2294

← 1 2 3 4 5 6 7 8 9 10 →